MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the year ending 2025-12-31.

Cash Flow Overview

Free Cash flow
-$110,440K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
Revenues
216,105
Cost of goods sold excluding amortization
13,044
Research and development
109,271
Selling, general and administrative
237,951
Intangible asset amortization
7,007
Other income
12,521
Provision (benefit) for income taxes
81,827
Net income (loss)
-220,474
Depreciation of property and equipment
1,103
Stock-based compensation
9,474
Amortization of premiums and accretion of discounts on marketable securities
2,053
Loss on sales of marketable securities
0
Intangible asset amortization
7,007
Right-of-use asset amortization
3,807
Deferred income taxes
81,443
Other non-cash adjustments, net
-1,943
Accounts receivable
7,463
Prepaid expenses and other assets
12,067
Inventory
3,466
Accounts payable and other liabilities
15,820
Product revenue allowances
15,484
Net cash provided by (used in) operating activities
-109,442
Asset acquisition
0
Purchases of property and equipment
998
Purchases of marketable securities
112,379
Sales and maturities of marketable securities
208,237
Net cash provided by (used in) investing activities
94,860
Principal payments on finance leases
1,991
Tax obligations paid in connection with settlement of restricted stock units
915
Net cash provided by (used in) financing activities
-2,906
Effect of exchange rate changes on cash, cash equivalents and restricted cash
23
Net change in cash, cash equivalents and restricted cash
-17,465
Cash and cash equivalents at beginning of period
102,785
Cash and cash equivalents at end of period
85,320
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. (VNDA)